Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

121.41 +2.17 (+1.82%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results

Today 17:09 EST

Moderna Inc. (NASDAQ: MRNA) shares jumped 8% in early trading on February 13, 2026, after the biotechnology pioneer reported fourth-quarter 2025 financial results that exceeded Wall Street’s...

Via MarketMinute

Topics Earnings

Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug? ↗

Today 10:35 EST

Eli Lilly announced an acquisition of an innovative new autoimmune drug.

Via The Motley Fool

Dow Jones 267-Point Slide: Blue-Chip Leaders and the AI Reality Check

Today 10:27 EST

The Dow Jones Industrial Average endured a chilling session this Friday, February 13, 2026, dropping 267.77 points, or 0.54%, to close at 49,184.21. The slide marked the second consecutive day of...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Merck & Co. Inc. (NYSE:MRK) Beats Q4 Estimates but 2026 Outlook Cautions Investors ↗

February 03, 2026

Via Chartmill

3 Mega-Cap Stocks for Long-Term Investors

February 12, 2026

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their...

Via StockStory

Topics Supply Chain

The Great Rebound: US M&A Market Ignites as Megadeals Surge 111% in AI-Driven Supercycle

February 12, 2026

The United States merger and acquisition (M&A) landscape has entered a transformative era in early 2026, marking a definitive end to the deal-making drought that plagued the previous two years. Driven...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

The Great Rotation: Healthcare Emerges as the S&P 500’s New Crown Jewel in 2026

February 12, 2026

As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Zoetis Inc. (ZTS): Navigating Innovation and Safety in a Mature Animal Health Market

February 12, 2026

Zoetis Inc. (NYSE: ZTS) stands today as the undisputed global leader in animal health, a position it has fortified since its historic decoupling from Pfizer over a decade ago. As of February 12, 2026,...

Via Finterra

Topics Artificial Intelligence Earnings Economy

The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation

February 12, 2026

The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of...

Via Finterra

Topics Initial Public Offering Intellectual Property

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

February 12, 2026

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

February 11, 2026

From Merck & Co., Inc.

Via Business Wire

AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse

February 10, 2026

On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the...

Via Finterra

Topics Economy Intellectual Property

5 Revealing Analyst Questions From Merck’s Q4 Earnings Call

February 10, 2026

Merck’s fourth quarter was marked by continued demand for its oncology and cardiometabolic franchises, as well as the impact of several new product launches and strategic acquisitions. Management...

Via StockStory

Topics Earnings Intellectual Property

Stock Market Today, Feb. 9: Oracle Climbs on AI Optimism Despite Software Sector Weakness ↗

February 09, 2026

On Feb. 9, 2026, Oracle's AI-fueled advance helped steady major U.S. indexes as software lagged and traders eyed key macro data.

Via The Motley Fool

Topics Artificial Intelligence Economy Stocks

3 Top Dow Jones Dividend Stocks to Buy for Passive Income in 2026 ↗

February 08, 2026

You always get what you pay for, so don't be afraid to pay up for a little more quality.

Via The Motley Fool

Topics Economy Intellectual Property Stocks

AstraZeneca’s Strategic Takeover of Modella AI Signals the Rise of Agentic Oncology

February 06, 2026

In a move that underscores the pharmaceutical industry’s aggressive pivot toward integrated artificial intelligence, AstraZeneca (NASDAQ: AZN) recently announced the full acquisition of Modella AI, a...

Via TokenRing AI

Topics Artificial Intelligence

Fiscal Brinkmanship: Data Blackout and the DHS Cliff Loom Over Markets After Narrow Funding Deal

February 06, 2026

In a week defined by high-stakes political theater and a brief but disruptive lapse in federal operations, Washington has managed to pull back from the edge of a total collapse—though only partially....

Via MarketMinute

Topics Economy Government Immigration

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance

February 06, 2026

As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade...

Via Finterra

Topics Economy Government Intellectual Property

Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗

February 05, 2026

The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes...

Via Stocktwits

Topics Economy Government World Trade

USDA Unveils $100 Million 'Grand Challenge' to Thwart Flesh-Eating Screwworm as Threat Reaches U.S. Border

February 05, 2026

In a decisive move to protect the nation’s multi-billion dollar livestock industry, U.S. Secretary of Agriculture Brooke Rollins announced today, February 5, 2026, the launch of a $100 million "New...

Via MarketMinute

Topics Death Economy

AI Panic Hits Software, PayPal Faceplants, Walmart Joins the $1T Club ↗

February 04, 2026

Via Chartmill

Topics Artificial Intelligence

How Merck Is Preparing For The Patent Cliff Of Its Blockbuster Cancer Drug Keytruda ↗

February 04, 2026

Scotiabank lifted its Merck target to $136 and kept an ‘Outperform’ rating, implying a 17% upside.

Via Stocktwits

Topics Earnings Intellectual Property

MRK Q4 Deep Dive: Pipeline Expansion and New Product Launches Shape Guidance

February 04, 2026

Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue...

Via StockStory

Merck (MRK) Q4 2025 Earnings Call Transcript ↗

February 03, 2026

Merck (MRK) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Merck’s (NYSE:MRK) Q4 CY2025 Sales Beat Estimates

February 03, 2026

Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue...

Via StockStory

Topics Earnings

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

February 03, 2026

From Merck & Co., Inc.

Via Business Wire

The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs

February 02, 2026

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those...

Via MarketMinute

Topics Economy Government Intellectual Property

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.